FDA approves Travere's Filspari as first drug for the kidney disease called FSGS

Nicole DeFeudis / endpoints - The FDA expanded the label for Filspari on Monday to add another kidney condition. The drug is now the first therapy approved in the US for focal segmental glomerulosclerosis (FSGS). The pill may be taken ...

AI Summary: The FDA approved Filspari for focal segmental glomerulosclerosis (FSGS), delivering the first specifically authorized treatment for this rare kidney disease. The approval provides a targeted therapeutic option for patients and marks a commercial milestone for Travere, raising hopes for better outcomes while spotlighting questions about access, pricing, and long‑term real‑world effectiveness.

---

Warning: Undefined variable $thumbnail in /home3/thegood9/public_html/website_70aad9ea/cluster.php on line 61

Related Stories

---

Warning: Undefined variable $top_stories in /home3/thegood9/public_html/website_70aad9ea/cluster.php on line 128

FDA again rejects Aldeyra’s dry‑eye drug for weak evidence / 2 months

FDA approves Merck’s once‑daily two‑drug HIV pill, shaking up market / 5 wks

BioMarin Phase 3 failure dims hopes for rare‑disease therapy / 8 days

Insmed shelves Brinsupri in skin indication after mid‑stage flop / 7 wks

Datroway secures regulatory approvals in breast cancer across US and EU / 8 days

BeOne’s BCL2 inhibitor gains FDA approval challenging Venclexta / 15 days

FDA clears AstraZeneca’s new blood-pressure drug baxdrostat / 13 days